How much funding has Affinia Therapeutics raised?

Affinia Therapeutics has raised $210.0M in total funding, most recently a Series C round.

Who are Affinia Therapeutics's investors?

Affinia Therapeutics's investors include New Enterprise Associates, F-Prime Capital, EcoR1 Capital, Farallon Capital, Atlas Venture, Eli Lilly & Company.

When was Affinia Therapeutics founded?

Affinia Therapeutics was founded in 2019.

Where is Affinia Therapeutics headquartered?

Affinia Therapeutics is headquartered in Waltham, Massachusetts, United States.

What industry is Affinia Therapeutics in?

Affinia Therapeutics operates in Biotech, Therapeutics.

How many employees does Affinia Therapeutics have?

Affinia Therapeutics has 51-200 employees.

Affinia Therapeutics

Expanding what's possible in AAV gene therapy today.

Waltham, United States · Founded 2019 · $210.0M raised

Biotech

Therapeutics

Headquarters: Waltham, Massachusetts
Employees: 51–200
Founded: 2019
Business Model: B2B

Website: affiniatx.com
Total Funding: $210.0M
Last Round: $40.0M Series COct 2025
Rounds: 3

About

Affinia Therapeutics pioneers rationally designed AAV gene therapies for rare and prevalent diseases, focusing on heart and nervous system disorders. Using AI and structural modeling, their ART platform creates novel capsids for improved tissue targeting, safety, and efficacy. Their lead program AFTX-201 targets BAG3-associated dilated cardiomyopathy.

Summary

Affinia Therapeutics is a Biotech company based in Waltham, United States, founded in 2019. It has raised $210.0M in total across 3 rounds, most recently a $40.0M Series C round in Oct 2025. Investors include New Enterprise Associates, F-Prime Capital and EcoR1 Capital.